Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer's disease
(AD), and its accumulation has been considered as the molecular driver of Alzheimer's …

The human gastrointestinal tract is populated with a diverse microbial community. The vast
genetic and metabolic potential of the gut microbiome underpins its ubiquity in nearly every …

Cognitive dysfunction is often reported in patients with post-coronavirus disease 2019
(COVID-19) syndrome, but its underlying mechanisms are not completely understood …

Background Synaptic degeneration occurs in the early stage of Alzheimer's disease (AD)
before devastating symptoms, strongly correlated with cognitive decline. Circular RNAs …

Aims Memory impairment is a major clinical manifestation in Alzheimer's disease (AD)
patients, while regular exercise may prevent and delay degenerative changes in memory …

Synaptic dysfunction caused by soluble β‐amyloid peptide (Aβ) is a hallmark of early‐stage
Alzheimer's disease (AD), and is tightly linked to cognitive decline. By yet unknown …

Background Chronic cerebral hypoperfusion (CCH) is a frequently observed underlying
pathology of both Alzheimer's disease (AD) and vascular dementia (VD), which is a common …

Alzheimer's disease (AD) is a neurodegenerative disease and the world's primary cause of
dementia, a condition characterized by significant progressive declines in memory and …

Alzheimer's Disease (AD) is the most common neurodegenerative disease which manifests
with progressive cognitive impairment, leading to dementia. Considering the noninvasive …

Alzheimer's disease (AD) is a neurodegenerative disorder that leads to cognitive decline
and memory loss. Unfortunately, there is no effective treatment for this condition, so there is …